Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
NCT ID: NCT03768037
Last Updated: 2018-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
106 participants
INTERVENTIONAL
2018-11-26
2020-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anlotinib plus Pemetrexed
Anlotinib plus Pemetrexed
Anlotinib plus Pemetrexed
Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.
Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Pemetrexed
Pemetrexed
Pemetrexed
Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anlotinib plus Pemetrexed
Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.
Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Pemetrexed
Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with advanced or recurrent non-squamous NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using RECIST 1.1)
* No prior systemic treatment for non-squamous NSCLC
* Negative in EGFR\&ALK\&ROS1
* Main organs function is normal
Exclusion Criteria
* Symptoms of brain metastases cannot be controlled and treated within less than 21 days
* Have participated in other clinical trials of anti-tumor medicine within 4 weeks
* Get any severe diseases or the ones that cannot be controlled
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Association of Clinical Trials
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chest Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shucai Zhang
Role: primary
Zhe Liu
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTONG1801
Identifier Type: -
Identifier Source: org_study_id